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Background: Surfactant therapy is one of the few treatments that have dramatically changed clinical practice in
neonatology. In addition to respiratory distress syndrome (RDS), surfactant deficiency is observed in many other
clinical situations in term and preterm infants, raising several questions regarding the use of surfactant therapy.
Objectives: This review focuses on several points of interest, including some controversial or confusing topics
being faced by clinicians together with emerging or innovative concepts and techniques, according to the state
of the art and the published literature as of 2013. Surfactant therapy has primarily focused on RDS in the preterm
newborn. However, whether this treatment would be of benefit to a more heterogeneous population of infants
with lung diseases other than RDS needs to be determined. Early trials have highlighted the benefits of
prophylactic surfactant administration to newborns judged to be at risk of developing RDS. In preterm newborns
that have undergone prenatal lung maturation with steroids and early treatment with continuous positive airway
pressure (CPAP), the criteria for surfactant administration, including the optimal time and the severity of RDS, are
still under discussion. Tracheal intubation is no longer systematically done for surfactant administration to
newborns. Alternative modes of surfactant administration, including minimally-invasive and aerosolized delivery,
could thus allow this treatment to be used in cases of RDS in unstable preterm newborns, in whom the tracheal
intubation procedure still poses an ethical and medical challenge.
Conclusion: The optimization of the uses and methods of surfactant administration will be one of the most
important challenges in neonatal intensive care in the years to come.
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on the most controversial and confusing topics being
faced by clinicians today, and emerging or innovative
concepts and techniques regarding the use of surfactant
therapy in respiratory management.
A systematic PubMed search up to January 2013 was
undertaken to identify manuscripts addressing the following
three specific questions:
1. Which infants should we treat with exogenous
surfactant therapy?
2. When should preterm infants with RDS be treated
with exogenous surfactant?td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with exogenous surfactant?Which infants should we treat with exogenous
surfactant therapy?
Surfactant therapy for primary surfactant deficiency
Surfactant therapy for RDS in the preterm newborn
Surfactant synthesis starts early in fetal life and increases
with gestational age. Over the last 10 years, meta-analyses
have confirmed that exogenous surfactant treatment
decreases overall morbidity and mortality in preterm
newborns with RDS [2,3]. Both animal and human
studies have demonstrated that early administration of
surfactant is more effective than later rescue surfactant
treatment because of better surfactant distribution and
avoidance of ventilator-induced lung injury [4,5]. As of
today, the questions that remain concerning surfactant
therapy in preterm infants with RDS revolve around
the identification of infants requiring surfactant, and the
delivery method and dosage of surfactant administration.
Indeed, emergency tracheal intubation in the delivery
room for prophylactic or early surfactant administration
raises ethical issues regarding pain management and
the side effects induced by the procedure [6-8]. Other
aspects of surfactant delivery, including the volume of
surfactant administered, the rapidity of administration,
drug viscosity and delivery rate, are also of interest.
Finally, potential methods for the selection of infants
with surfactant deficiency despite antenatal exposure to
steroids include the stable microbubble test [9] and the
click test, leading to earlier administration and reduced
surfactant use [10].Exogenous surfactant therapy for newborns of
diabetic mothers
Epidemiological studies have shown that the risk of RDS
is 5.6 times greater in newborn infants of diabetic
mothers than in infants of non-diabetic mothers [11].
Although the strict management of maternal diabetes has
reduced the incidence of RDS in very preterm infants
of mothers with pregestational and gestational diabetes
mellitus, pathophysiological data suggest that lung
maturation is delayed in this population. In addition,
although some studies show normal levels of disaturated
phosphatidylcholine (DSPC), the main component of
surfactant, in the amniotic fluid of diabetic pregnant
women [12], others have revealed a decrease in DSPC
levels in these pregnancies [13]. Even though these epi-
demiological and pathophysiological data suggest that
the use of surfactant therapy would be beneficial in
newborns born to diabetic mothers, no prospective study
has as yet been performed in this population.Newborns with genetic mutations in surfactant proteins
Lung diseases associated with surfactant metabolism
dysfunctions represent a heterogeneous group of rare
disorders [14], usually with poor prognosis and weak or
transient effects of mechanical ventilation or exogenous
surfactant therapy [15]. These conditions are rarely known
before birth unless there has been a previously affected
infant. The inherited deficiency of pulmonary surfactant B
protein (SP-B) was first described in term newborns with
RDS in 1993 [16]. Since then, other genetic mutations in
surfactant proteins have been described, of which some
induce RDS in newborns within the first few days of life
while others result in lung diseases in older infants.
These include mutations of the surfactant protein C
(SP-C) gene [17], mutations in proteins required for
surfactant synthesis, such as the ATP-binding cassette
transporter, subfamily A, member 3 (ABCA3) [18] or the
NK2 homeobox protein NKX2-1, a critical regulator
of the transcription of SP-B and SP-C [19]. Steroids,
hydroxychloroquine and azithromycin have been proposed
in older patients, but little information is available to assess
the benefit/risk ratio of these treatments.
Surfactant therapy for secondary surfactant deficiency
Various clinical situations such as pulmonary haemorrhage,
meconium aspiration syndrome (MAS), pulmonary in-
fection and atelectasis have been shown to liberate
inflammatory mediators that damage type II pneumocytes
and inactivate surfactant [20,21]. Surfactant replacement
therapy could thus be useful as a supporting treatment in
this population of newborns with secondary or transient
surfactant deficiency.
Surfactant therapy in term and near-term newborns with
acute respiratory distress syndrome (ARDS)
The incidence of ARDS requiring mechanical ventilation
in term and near-term newborns is 7.2/1000 live births,
and 30% of newborns requiring mechanical ventilation
in the neonatal intensive care unit (NICU) are low birth-
weight infants [22]. The incidence of ARDS decreases
from 10.5% (390/3700) for infants born at 34 weeks of
gestation to 0.3% (140/41,764) at 38 weeks [23]. The
incidence of respiratory morbidity is significantly higher in
newborns delivered by caesarean section before the onset
of labour (35.5/1000) than in those delivered by caesarean
section during labour (12.2/1000) or in vaginal births
(5.3/1000) [24]. Even among deliveries by caesarean
section before the onset of labour, a significant reduction
in the incidence of ARDS could be obtained if elective
caesarean section is performed after the 39th week of
gestation [24,25]. Even if the overall incidence of ARDS
seems low in term and near-term newborns, these still
constitute a high-risk population with significant neonatal
mortality and morbidity including air leaks, severe
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bronchopulmonary dysplasia [26]. The mechanisms
leading to ARDS in term or near-term newborns
involve delayed lung liquid clearance and insufficient
surfactant production. Similarly, term infants with
transient tachypnea of the newborn have low lamellar
body counts associated with decreased surfactant function,
suggesting that prolonged disease is associated with
surfactant abnormalities [27].
Surfactant therapy for newborns with pulmonary
haemorrhage
Experimental data suggest that the molecular components
involved in pulmonary haemorrhage can biophysically
inactivate endogenous lung surfactant, whereas exogenous
surfactant replacement is capable of reversing this process
even in the continued presence of inhibitor molecules
[28,29]. In two clinical studies, whose control groups were
not comparable, the mean oxygenation index improved
in preterm and term infants who received surfactant
following clinically significant pulmonary haemorrhage,
with no deterioration in the condition of any patient
[30,31]. Case reports have also noted the successful use
of surfactant treatment after idiopathic [32] or iatro-
genic pulmonary haemorrhage [33]. However, a recent
Cochrane meta-analysis found no any randomized or
quasi-randomized trials evaluating the effects of surfactant
in pulmonary haemorrhage in neonates [34], suggesting
the need for such trials.
Surfactant therapy in meconium aspiration syndrome (MAS)
MAS is characterized by the early onset of respiratory
distress in meconium-stained infants, resulting in high
pulmonary morbidity and mortality [35,36]. The patho-
physiology of MAS includes airway obstruction [37,38],
alveolar inflammation [39] and surfactant inhibition [40,41].
Over the last 10 years, cohort studies assessing the use of
treatments such as High-Frequency Oscillatory Ventilation
(HFOV) or inhaled Nitric Oxide (iNO) in MAS have not
revealed any decrease in the duration of ventilation or
oxygen therapy [42,43].
Surfactant treatment has been proposed in MAS, either
as a bolus treatment or surfactant lavage. In one meta-
analysis, bolus surfactant treatment for MAS decreased the
need for extracorporeal membrane oxygenation (ECMO)
(NNT=6), but had no statistically significant effect on
mortality, duration of assisted ventilation, duration of
supplemental oxygen, pneumothorax, pulmonary inter-
stitial emphysema, air leaks, chronic lung disease, need
for oxygen at discharge or intraventricular haemorrhage
[44]. Surfactant lavage has been performed in several
animal and human studies, with an optimal total lavage
fluid volume of 15 to 30 mL/kg [35,45,46]. The surfactant
was diluted in these studies in physiological saline toobtain a final phospholipid concentration of 5 mg/mL
[47]. In a recent meta-analysis of surfactant lavage,
Hahn et al. state that lung lavage with diluted surfactant
may be beneficial to infants with MAS, but additional
controlled clinical trials of lavage therapy should be
conducted to confirm this effect, to refine the method
of lavage, and to compare lavage with other approaches
[48]. In a study of newborn lambs with respiratory failure
and pulmonary hypertension induced by MAS, gas
exchange and lung compliance were improved by lung
lavage with dilute surfactant but not by bolus treatment
[49]. Given these results, it is safe to conclude that sur-
factant treatment, either as a bolus or diluted for lung
lavage, would decrease the need for ECMO in human
newborns with MAS. Furthermore, in infants with MAS,
if ECMO is not available, surfactant administration may
reduce the severity of respiratory illness and decrease the
number of infants with progressive respiratory failure
requiring support with ECMO. Larger clinical trials are
necessary to confirm that surfactant may be an effective
treatment for the aspiration of several biological fluids
in addition to meconium, including blood, vernix and
amniotic fluid.
Surfactant therapy for impaired lung alveolarization
Both congenital and acquired lung growth impairments
result in a decrease in lung alveolarization, type II
pneumocyte counts and surfactant production [50-52],
suggesting a potential benefit from surfactant replace-
ment therapy.
Exogenous surfactant therapy for congenital diaphragmatic
hernia (CDH)
Newborns with CDH display pulmonary hypoplasia with
persistent pulmonary hypertension (PPH), resulting in a
high incidence of respiratory morbidity and mortality
[53,54]. Animal models of CDH have revealed a deficient
surfactant system [50,55,56]. In human studies, Boucherat
et al. have shown that CDH does not impair storage in
fetuses [57]. CDH lungs exhibit no trend towards a
decrease in content or a delay in developmental changes
for any of the surfactant components or surfactant mat-
uration factors studied. Data from cohorts of newborns
with a prenatal diagnosis of isolated CDH do not show
any benefit associated with surfactant therapy [53].
However, surfactant phosphatidylcholine synthesis is
decreased in newborns with CDH who require ECMO
after birth [58]. A plausible explanation for the difference
in surfactant synthesis is that CDH infants who require
ECMO have more severe pulmonary hypoplasia compared
to CDH infants who do not require ECMO. Systematic
surfactant therapy can thus not be recommended for
term newborns with a prenatal diagnosis of isolated CDH.
Whether surfactant therapy is beneficial or not in preterm
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should be evaluated in randomized trials that also take
into account the severity of the underlying lung hypoplasia
and gestational age at delivery.
Late surfactant therapy for chronically ventilated
preterm infants
In spite of early exogenous surfactant treatment, extremely
low birth weight infants can develop persistent respiratory
failure during the first weeks of life, leading to broncho-
pulmonary dysplasia (BPD) and alveolarization defects
[52]. Surfactant proteins are involved in the pulmonary
host defence and response to lung injury. The synthesis
of surfactant proteins has been found to be decreased
in animal models of BPD [59]. Preterm infants requiring
chronic ventilation after 7 days of life also present dys-
functional surfactant proteins [60].
Studies evaluating the effects of surfactant administration
in chronically ventilated preterm infants have demonstrated
a short-term beneficial effect on the fraction of inspired
oxygen (FiO2) and the respiratory distress severity score at
48 and 72 hours [61]. However, the sole study to evaluate
the effect of late surfactant treatment on the incidence
of BPD or mortality has reported trends toward lower
morbidity/mortality only in infants who received high
dose of lucinactant [62].
When should preterm infants with rds be treated
with exogenous surfactant?
The optimal timing (prophylactic or selective) for the
administration of surfactant to preterm infants with RDS
has been assessed by many studies, and discussed in
recent reviews [63]. On the basis of these studies, various
guidelines have been elaborated by national expert
committees in accordance with current practice and
conclusions drawn from recent large trials of CPAP.
Prophylactic vs. selective surfactant treatment
Rojas-Reyes et al. [5] have carried out a meta-analysis
comparing the effectiveness of prophylactic vs. selective
exogenous surfactant administration in preventing mor-
bidity and mortality in very preterm infants below 30–32
weeks gestational age (GA). Prophylactic administration
decreases the incidence of pneumothorax, pulmonary
interstitial emphysema, neonatal mortality and BPD or
death to a greater extent than selective treatment.
However, several limitations of this meta-analysis should
be noted: (i) the range of gestational ages studied was
large, (ii) the exogenous surfactant used was natural
but was different in each study, and (iii) the timing of
selective surfactant administration was very different
among the studies, from 1 hour to 24 hours after birth. In
addition, the beneficial effect of prophylactic surfactant
on neonatal mortality or air-leak syndromes was onlyseen in infants not routinely subjected to CPAP. Finally,
the increasing use of antenatal betamethasone in the
current era could be an explanation for the lower impact
of prophylactic surfactant.
Early vs. late surfactant treatment
The benefits of early (< 2 hours) and delayed (> 2 hours)
surfactant administration have been recently reviewed
[4] in a meta-analysis of six randomized controlled trials
(RCTs), consisting of two trials with synthetic (Exosurf
Neonatal) and four using animal-derived surfactant pre-
parations [64-69]. According to this meta-analysis, early
selective surfactant administration to infants with RDS
requiring assisted ventilation leads to a decreased risk of
acute pulmonary injury (decreased risk of pneumothorax
and pulmonary interstitial emphysema) and a decreased
risk of neonatal mortality and chronic lung disease,
compared to delaying treatment of such infants until
they develop worsening RDS.
More recently, two new RCTs have demonstrated
that routine early surfactant administration within 2
hours of life:
– reduces the need for mechanical ventilation in the
first week of life among preterm infants with RDS on
nasal CPAP, born between 28 and 32 weeks GA [70],
– decreases intra-ventricular haemorrhage (≥ grade
III) and pneumothorax rates but does not have any
effect on BPD when compared to delayed surfactant
administration [71].
National guidelines for exogenous surfactant administration
Table 1 summarizes national recommendations for
surfactant prophylactic use. The British Association of
Perinatal Medicine recommended in 1999 that very
preterm infants, born before 32 weeks GA be treated
with exogenous surfactant at birth only if they needed
intubation, and that all very preterm infants below 29
GA be intubated for the administration of exogenous
surfactant [72]. More recently, in 2008, the American
Academy of Pediatrics Committee on the Fetus and
Newborn has recommended using surfactant in infants
with RDS as soon as possible after intubation, irrespective
of exposure to antenatal steroids or gestational age. They
have also recommended that prophylactic surfactant
treatment be administered to extremely preterm infants
(< 28 weeks GA) at high risk of RDS, especially infants
who have not been exposed to antenatal steroids [73].
The Canadian Paediatric society has advocated that
intubated infants with RDS receive exogenous surfactant
therapy, and that infants at significant risk of RDS receive
prophylactic surfactant treatment as soon as they are
stable, within a few minutes of intubation [74]. The
consensus guidelines developed by European experts in
Table 1 International guidelines for RDS treatment
Country (ref) Year Gestational age Prophylactic use of surfactant
UK (72) 1999 < 29 weeks Systematic
< 32 weeks If need for intubation at birth
Canada (74) 2005 < 26 weeks Systematic
26-27 weeks If no antenatal steroids
US (73) 2008 < 28 weeks Systematic
Europe (75–76) 2010-2013 < 26 weeks Systematic
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tration to all extremely preterm infants born at less than
26 weeks GA and to all preterm infants with RDS who
require intubation for stabilization. In addition, they
recommend that early rescue surfactant therapy be
administrated to untreated preterm infants with RDS
[75]. In a recent update of European consensus guidelines
on the management of neonatal respiratory distress
syndrome in preterm infants, the experts state that the
best preparation, optimal dose and timing of surfactant
administration at different gestational ages is not com-
pletely clear. In addition, the use of very early CPAP
has altered the indications for prophylactic surfactant
administration [76].
A European survey conducted in 2011 has analysed
the incorporation of guidelines for surfactant therapy
into clinical practice in 173 NICUs across 21 European
countries [77]. Only 39% of the NICUs used prophylactic
treatment. Twenty-three % of preterm infants received
their first surfactant dose within the first 15 minutes after
birth, while 28% of them received it after 2 hours of life. A
gestational age of less than 28 weeks and a birth weight of
less than 1000 g were used as criteria for prophylactic
treatment in most of NICUs. Eighty eight % used a median
FiO2 of greater than 0.40 as the indication for rescue
surfactant treatment, at a median time of 2 hour after birth.
CPAP vs. intubation for exogenous surfactant infusion in
the age of antenatal corticosteroids
There is increasing evidence to suggest that CPAP
immediately after birth is a reasonable alternative to
systematic intubation for surfactant administration to
preterm infants. Recent trials on this topic are sum-
marized in Table 2.
Morley et al. [78] demonstrated, in the COIN trial,
that early nasal CPAP did not reduce the rate of death
or BPD, but the need for intubation and use of surfactant
were halved (38% vs. 77%; p<0.001) in extremely preterm
infants. This study suggests that starting respiratory
support with CPAP did not adversely affect infants even
if the incidence of pneumothorax was increased in the
CPAP group when compared with the intubation group
(9% vs. 3%; p<0.001). Rojas et al. [79] conducted a
trial showing that an “intubation-very early surfactantadministration-extubation” sequence improved outcome
in very preterm infants by decreasing the need for mech-
anical ventilation and the incidence of air-leak syn-
dromes, when compared with CPAP therapy alone. In the
CURPAP trial [80], prophylactic surfactant administration
to very preterm infants was not superior to CPAP or early
selective surfactant treatment in reducing the need for
mechanical ventilation, pneumothorax, BPD or mortality.
In the SUPPORT trial [81], the authors randomized
1316 infants born at 24–27 weeks GA into two groups:
a CPAP group and a surfactant group (intubation and
prophylactic surfactant administration). The primary
outcome (death or BPD at 36 weeks) did not differ sig-
nificantly between the two groups. In addition, a high
proportion (46%) of infants assigned to the “initial CPAP”
group still ended up being intubated and receiving
surfactant. Dunn et al. [82] compared 3 strategies for
initial respiratory management in infants born between
26 and 29 weeks GA: 1) prophylactic surfactant adminis-
tration followed by mechanical ventilation, 2) intubation-
early surfactant use-extubation and 3) initial CPAP with
selective surfactant treatment. The incidence of death
or BPD at 36 weeks was similar in the 3 groups. No
significant differences were found at 18 to 22 months
of corrected age with regard to the composite outcome
of death or neurodevelopmental impairment between
extremely premature infants randomly assigned to early
CPAP or early surfactant administration and to a lower
or higher target range of oxygen saturation [83]. These
controlled studies demonstrate that early CPAP use
safely reduces the number of infants intubated and treated
with surfactant compared to prophylactic surfactant
administration or the intubation-surfactant-extubation
approach. Unfortunately, neither the SUPPORT nor the
COIN trial helps to identify infants at birth who, if initially
ventilated using CPAP, will subsequently require intub-
ation and ventilation.Prophylactic vs. selective surfactant administration in the
age of antenatal corticosteroids and CPAP
Rojas-Reyes et al. [5] have recently updated a meta-
analysis comparing the effects of prophylactic surfactant
with selective surfactant treatment. The benefits of the
Table 2 Recent studies concerning CPAP and surfactant administration
Study (ref) Year N Population Outcome Groups
COIN Trial (78) 2008 610 25-28 wks CPAP Systematic intubation
Death or BPD 33.9% 38.9%
Intubation 46% 100%
Selective surfactant 38%*** 77%
Pneumothorax 9%*** 3%
Rojas et al. (79) 2009 279 27-31 wks CPAP Intubation-earlysurfactant-extubation
Need for MV 39%* 26%
Pneumothorax 9% 2%
Rescue surfactant 26%** 12%
BPD at 36 wks PMA 59% 49%
CURPAP Trial (80) 2010 208 25-28 wks CPAP Early selective Surfactant Prophylacticsurfactant
Need for MV 33% 31.4%






(81) 2010 1316 24-28 wks CPAP
Intubation-early
surfactant use
Death or BPD 48.7% 54.1%
Surfactant use 67.1%*** 98.9%
Air leak 6.8% 7.4%





Surfactant use 14.8%*** 98.6% 98.2%
Death or BPD 30.5% 36.5% 28.5%
Pneumothorax 5.4% 4.8% 3.2%
BPD=bronchopulmonary dysplasia, PMA=postmenstrual age, MV=mechanical ventilation; wks: weeks of gestation.
*:p<0.05; **:p<0.01; ***:p<0.001.
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first meta-analysis are not confirmed by this updated
meta-analysis. Recent large trials that reflect the current
increase in antenatal corticosteroid administration and
routine post-delivery stabilization on CPAP also do not
support these benefits.
In summary, early selective surfactant treatment in
preterm infants with RDS is more effective than delayed
selective surfactant use in reducing neonatal mortality,
pneumothorax, and BPD at 36 weeks. Prophylactic treat-
ment also decreases the incidence of pneumothorax,
pulmonary interstitial emphysema, BPD and neonatal
mortality when compared with delayed selective treat-
ment. However, prophylactic surfactant treatment is not
superior to initial respiratory support with CPAP followed
by selective surfactant treatment later on in reducing
the need for mechanical ventilation, pneumothorax and
BPD or mortality in the era of antenatal corticosteroids
and CPAP.How should preterm infants with rds be treated
with exogenous surfactant: InSurE or MIST?
The “InSurE” strategy
The InSurE approach is a strategy in which surfactant is
administered during brief intubation followed by immedi-
ate extubation and nasal respiratory support. This strategy
has been shown in earlier RCTs to halve the need for sub-
sequent mechanical ventilation. More recently, Bhandari
et al. have demonstrated that the InSurE strategy is associ-
ated with a significantly lower incidence of BPD or death
(20% vs. 52%; p=0.03) [84].
A Cochrane review updated in 2007 has compared
InSurE with later selective surfactant use. The InSurE
strategy is associated with a significantly lower incidence
of mechanical ventilation and a trend towards a decrease
in BPD and air-leak syndromes [85]. Rojas et al. evaluated
very early surfactant administration with early CPAP in
very preterm infants [79]. In the InSurE group, the need
for mechanical ventilation was significantly lower and
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the incidence of BPD did not reach statistical significance.
Dani et al. have identified the clinical characteristics that
could predict the success or failure of InSurE in infants
[86]. Gestational age, birth weight and the need for oxygen
are independent risk factors for InSurE failure in infants.
Kirsten et al. have also reported in a recent observational
study that early neonatal outcome in extremely immature
infants may be improved by the administration of ante-
natal steroids as well as the InSurE strategy [87].
Taken together, these various studies demonstrate that
InSurE is a safe and effective method that reduces the
need for mechanical ventilation, the duration of respiratory
support and the need for surfactant replacement in
preterm infants with RDS. It may also reduce the rate of
BPD and air-leak syndromes, but limited data are available
regarding cerebral oxygenation and the potential risk of
brain damage. This strategy needs to be individually
tailored in accordance with the infant’s maturity and
general clinical condition, the use of antenatal steroid
treatment, the severity of RDS and certain practical
considerations affecting the NICU.
Emerging techniques for surfactant administration
Considering the risks associated with the use of an endo-
tracheal tube (usually associated with premedication that
contributes to a delay in extubation), Minimally-Invasive
Surfactant Therapy (MIST) and Non-Invasive Surfactant
Therapy (NIST) are emerging methods for surfactant
administration without the need for positive-pressure
mechanical ventilation (Table 3) [88].
Should surfactant always be administered through an
endotracheal tube?
Intrapartum pharyngeal instillation
An initial multicenter trial tested surfactant administration
to the posterior pharynx immediately following birth,Table 3 Emerging approaches to surfactant administration
Emerging approaches Advantages





Easy to use (
NIST Aerosolization Painless
MIST: Minimally-Invasive Surfactant Therapy.
NIST: Non-Invasive Surfactant Therapy.before the first inspiration of air [89]. In this trial, the
solution was not administered under CPAP and many
of the subjects also received surfactant through an
endotracheal tube. More recently, 23 neonates born
between 27 and 30 weeks GA were treated by surfactant
instilled into the nasopharynx before the delivery of the
shoulders. Thirteen of 15 babies delivered vaginally were
weaned quickly to room air and required no further
surfactant or tracheal intubation for RDS. Evidence
from animal and observational human studies suggests
that the pharyngeal instillation of surfactant before the
first breath is potentially safe, feasible and effective.
Well-designed trials are still needed to confirm this [90].
Laryngeal mask
The laryngeal mask airway (LMA) is a supraglottic de-
vice used to administer non-invasive pressure ventilation
to adult, paediatric and neonatal patients. Trevisanuto
et al. used a laryngeal mask to deliver surfactant to 8
preterm and near-term infants with RDS and a birth
weight > 800 g [91], leading to an increased mean arterial/
alveolar oxygen tension ratio (a/APO2) without compli-
cations. The Cochrane review cited above [90] reported
no study of prophylactic surfactant administration using
an LMA. The Cochrane experts concluded that there was
some evidence that selective surfactant administration
through an LMA to preterm infants > 1200 g with estab-
lished RDS reduced oxygen requirement in the short term,
although the LMA technique needed to be further
evaluated in clinical trials, including those dedicated
to investigating the size of the LMA used according to
gestational age.
Feeding and vascular catheter
An alternative route for surfactant administration in
spontaneously breathing preterm infants on CPAP con-








CPAP Painful and traumatic
rigid catheter)
Technically challenging
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for the few minutes necessary to administer surfactant.
The first cases using this technique were reported by
Verder et al. [92]. A recent multicentre RCT including
very preterm infants has compared a standard group
(CPAP, rescue intubation and surfactant treatment if
needed) with an intervention group (surfactant via thin
catheter) [93]. According to this non-blinded trial, the
new method reduces the need for subsequent mechanical
ventilation on day 2 or 3 after birth, and the duration
of mechanical ventilation as well as the need for oxygen
therapy at 28 days. However, the risk of death or BPD
at 36 weeks does not differ between the two groups, and
the trial has prompted a few methodological concerns.
These findings may be of interest for infants that have
received antenatal steroids.
The use of a more stable vascular catheter (the Hobart
method) for surfactant administration allows easier place-
ment without the use of Magill forceps [94]. A preliminary
evaluation of this new technique in preterm infants showed
that surfactant was successfully administered and CPAP
quickly re-established, with decreasing FiO2. Transient
coughing (32%) and bradycardia (44%) were noted, and
44% of patients received positive-pressure inflation.
Multicentre RCTs of surfactant administration via cathe-
terization in preterm infants on CPAP are ongoing (the
OPTIMIST-A and -B trials). In active preterm infants, the
placement of a catheter without sedation may be difficult
and potentially traumatic. Guidelines for premedication
are therefore needed to minimize this risk.
Non-Invasive Surfactant Therapy (NIST): aerosolized surfactant
Within a few years of Patrick Kennedy’s death from RDS
in 1963, the first two trials reporting the use of synthetic
surfactants were published [95,96]. Both used nebulized
dipalmitoyl-phosphatidylcholine, with no discernible bene-
ficial effects. Since then, several pilot trials have been pub-
lished, but it has not been possible to clearly demonstrate
whether surfactant can be successfully administered via
nebulization [97]. To be effective, the surfactant would
have to be unaltered by the aerosolization process: i.e.
capable of being delivered to distal portions of the lung,
reaggregating, and maintaining its biological activity.
Several animal studies have directly compared aerosoliza-
tion to tracheal instillation, and reported that aerosoliza-
tion can be of equal or greater effectiveness [98], whereas
others have found that instillation is more effective than
aerosolization [99]. An example illustrating the need for
further clarity on this issue is the study by Lewis et al.
[100]. In sheep, exogenous bovine lung extract surfactant
was effective when instilled but ineffective when aero-
solized, whereas beractant in the same animal model
was more effective when aerosolized than when instilled.
Aerosol delivery to the alveoli in normal lungs is maximalin the particle-size range 0.5-2.0 μm, and it is possible
to generate a stable surfactant aerosol with that particle-
size range from aqueous or powdered surfactant [101].
Currently, 3 types of nebulizers are available: jet nebu-
lizers, ultrasound nebulizers and vibrating-membrane
nebulizers. If aerosol delivery technology for lung surfactant
could be perfected, this would clearly be a conceptually
attractive alternative to instillation for clinical application.
Indeed, aerosol delivery might avoid the transient endo-
tracheal tube obstruction and resultant hypoxia and
hypotension seen with bolus instillation. However, de-
livering aerosolized surfactant in sufficient quantities
and achieving its uniform distribution throughout the
alveoli of injured lungs in ventilated units is a key challenge.
Whether surfactant aerosolization can be accomplished
in a sufficiently effective and efficient manner to replace
instillation requires further direct comparisons in animals
and subsequently in human trials. A recent clinical study
using aerosolized lucinactant has demonstrated the
feasibility and safety of delivering this synthetic-peptide-
containing surfactant to newborns with early signs of
RDS [102]. Nebulized surfactant is potentially a therapeutic
option to avoid the severe volutraumatic and barotrau-
matic effects of mechanical ventilation. However, several
issues regarding cost-effectiveness, the development of
nebulizer devices capable of its administration, and dosing
strategies remain unresolved [103]. An open-label ran-
domized controlled pilot study to evaluate the safety and
efficacy of aerosolized porcine surfactant in the first hour
of life in preterm infants with RDS (CureNeb) is ongoing
in Australia. The primary outcomes evaluated are the
duration of mechanical ventilation and the need for
intubation.
In conclusion, surfactant administration via an endo-
tracheal tube remains the gold standard for surfactant
administration in intubated infants. However, CPAP, as
the primary respiratory support technique in infants with
RDS, has been shown to be at least as effective as
mechanical ventilation, and newly emerging techniques
for surfactant administration in non-ventilated infants
are currently under investigation. The optimization of a
less- or non-invasive method of surfactant administration
will be one of the most important challenges in the field of
surfactant therapy for RDS in the coming years.
Potential adverse effects and safety of exogenous
surfactant therapy
The short-term risks of surfactant administration include
bradycardia and hypoxemia during instillation, as well as
blockage of the endotracheal tube [104]. The relative risk
of pulmonary haemorrhage following surfactant therapy
has been reported at 1.47 (95% CI: 1.05 to 2.07) in trials
[105], but this adverse event is rarely reported in many of
the RCTs of surfactant administration. Moreover, a recent
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significant difference in the risk of pulmonary haemor-
rhage between prophylactic vs. selective administration
of surfactant [5]. Due to the very rapid improvement in
gas exchange in surfactant-treated infants, overdistension
and hyperventilation with low partial pressure of carbon
dioxide (PCO2) can occur. No other adverse clinical
outcome has been shown to be increased by surfactant
replacement. However, emerging techniques for surfactant
administration may give rise to new and unexpected
adverse events that must be taken into account in current
and future studies.
To date, there is no evidence that there are any im-
munological changes of clinical concern due to bovine
or porcine sources of proteins contained in natural sur-
factants [106].
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